A 58-Year-Old Man with Biochemically Recurrent Metastatic Castration-Sensitive Prostate Cancer - Episode 4

Comparing Approved Options for Androgen Inhibition in the mCSPC Setting

Discussion centered around androgen receptor inhibition/androgen synthesis inhibition and comparison of available, approved options for each.